StockWatch
·
KRATOS ENERGY & INFRASTRUCTURE LTD. · QQ2 FY-2027 · THE CALL

Multi-product pipeline offset by reporting credibility crisis

The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.

Q2 FY27 resultsLORDSMARKKRATOS ENERGY & INFRASTRUCTURE LTD.21 Nov 2026 · 6 min read
Verdict

Hold

confidence 5/10

Credibility

Grade C

FY27 1550 Cr revenue guidance maintained but PAT margins unverified. Reporting error erodes confidence in numbers.

Short-term outlook

Optimistic

next 1–2 quarters

Long-term outlook

Optimistic

multi-year

Strong multi-product pipeline (dialysis Renalyх, cancer screening, CAR-T, genomics) with 3-year revenue targets (FY29 ₹2,500 Cr) backed by 500+ machine orders and regulatory approvals. However, the company's publication of two different financial results with significant discrepancies, then a corrected letter to the exchange, is a governance red flag that undermines trust in reported numbers. Delivered Q2 PAT fell 48% QoQ despite revenue growth, and management's claimed PAT margin (11.88%) vastly exceeds delivered NPM (4.5%), signaling either a misstatement or a data accuracy issue.

₹375.7 Cr

Revenue · +2871.9% YoY

₹17.3 Cr

Reported PAT · +919.2% YoY

Compressing

Margins · vs guidance: Mixed

Did the claims hold up?

Management's claims vs. the numbers

Q2 consolidated revenue around 411 crores

OVERSTATED

Delivered result 375.7 ₹Cr — a 8.6% gap.

PAT margin 11.88%, higher than Q1's 10.78%

MISS

Delivered NPM 4.5% — massive gap; suggests claim conflates EBITDA margin, not PAT margin.

EBITDA 18.82%, slightly higher than prior quarter 17.6%

Unverified

Plausible but unverified by delivered result; PAT/NPM data contradict profitability claim.

50% of budgeted revenue already achieved in H1 FY27

Partial

Revenue H1 Jan-Sep: needs H1 exact number; claim suggests strong H1 momentum but QoQ PAT fell -48%.

500+ Renalyх dialysis machine export orders secured

MET

Specific order book cited; execution 6-9 months. No revenue yet, pre-launch trial phase.

Earnings quality

What changed since the last call

Deltas vs. the prior call

No numeric guidance change

Neutral

FY27 revenue target ₹1,550 Cr reiterated; FY27 PAT ₹170–175 Cr confirmed. No new FY28/FY29 numbers formally raised vs prior call.

Product pipeline accelerated

Upgrade

Dialysis machine 500+ orders now confirmed vs prior 'expected by FY27-end.' Cancer screening, CAR-T timelines brought forward to Q4 FY27–Q1 FY28.

Reporting credibility eroded

Downgrade

Two different Q2 result versions published with 'significant differences' (management quote). Board now monitoring future publications — governance issue.

The Q&A

Analysts pressed hard on reporting discrepancies (Gaurav, Anup), dialysis order timing and execution (Tejas), and competitive differentiation (Reyansh). Management largely answered directly on product specifics but deflected on stock price (constrained in commenting). Pushback was firm; management acknowledged error but did not provide granular details on controls remediation.

The exchanges that mattered

Reporting discrepancies — Gaurav

Partial

Error inadvertent; letter uploaded to exchange. Board set up monitoring committee for future publications. Management regretful but did not detail root cause or controls gap.

Dialysis machine orders — Gaurav

Answered

500+ export orders already there; 350 domestic orders in pipeline; execution 6–9 months. Total ~850 confirmed + inquiries. High confidence on deliverables.

FY27 revenue guidance — Hari Krishna Ravindran

Answered

FY27 targeting ₹1,550 Cr (conservative); FY29 ₹2,500 Cr on consolidated basis, possibly >₹3,000 Cr with Microtech scaling.

MedTech revenue split — Suresh Sheth

Partial

MedTech overall 60% of business. IVD/MedTech within that 10–15%. New products (dialysis, cancer screening) expected to lift MedTech share post-launch.

BARC cancer detection timeline — Sailesh Lodha

Answered

All three BARC-developed devices received test license. Onco Diagnoscope clinical trial March 27; CDSCO approval expected Q4 FY28.

Renalyх competitive differentiation — Sajal Raj

Answered

AI-enabled real-time monitoring; 30–40% lower cost of ownership vs imported machines; embedded OS platform for remote nephrologist guidance. Unique ecosystem.

Stock price pressure — Gaurav Mahajan

Dodged

Constrained in commenting on stock price; market dynamics, T2T segment dynamics possible. Work is to deliver performance; market will reflect growth.

Debt and CapEx plans — Vedansh

Answered

No ₹200 Cr debt raise. Promoter sold ~5% equity, re-infused ₹170 Cr. Biotech is separate entity, not a subsidiary; separate shareholders and directors.

Genomics and NGS plans — Arsh Suri

Answered

NGS currently outsourced. Three focus areas: preventive genomics, gut microbiome (CDSCO approved, launching Dec 27), pharmacogenomics. In-house NGS short-term unlikely.

Competitive moat — Reyansh Pandey

Answered

Innovation and technology differentiation (Renalyх AI, sickle cell test 15 min vs 72 hrs, Onco Diagnoscope oral cancer screening). Exclusive tech agreements with IIT Bombay. R&D and IP moat.

CapEx requirements — Tejas

Partial

CapEx adequately funded as of now. Promoter infused ₹170 Cr. IVD/MedTech factory (Vapi/Lucknow) and CAR-T centers planned for FY28 onwards.

Demerger timeline — Anup

Answered

Targeted March 27, but regulatory approval (NCLT) is gating. Likely March 27 or possibly Q1 FY28 at max.

Technology licensing exclusivity — Tejas

Partial

Exclusive agreements with IIT Bombay. Renalyх is proprietary. Commercialization cycle is long (design → trial → regulatory → manufacturing), so not easy to copy.

Guidance

Forward guidance and management's confidence

FY27 ₹1,550 Cr total revenue (conservative)

Medium

50% achieved in H1 (₹775 Cr run-rate assumption); remainder to come H2. Assumes dialysis, cancer screening launch success.

FY29 ₹2,500 Cr consolidated (possibly >₹3,000 Cr with Microtech scale)

Medium

Multi-product scaling (dialysis, cancer screening, CAR-T, genomics). Long execution cycle; regulatory risks remain.

FY28 PAT margin 10–11% (from prior guidance)

Low

Q2 delivered NPM 4.5%; claimed 11.88% contradicts delivered result. Assumes cost scaling and new product margin contribution.

CapEx for IVD/MedTech factory, CAR-T centers, dialysis manufacturing to be primarily FY28 onwards

Medium

Company stated adequately funded with promoter capital. Specific CapEx quantum not disclosed.

Risks the call surfaced

Ranked by how much they should concern a holder

Governance & reporting

High

Management published two different Q2 results with 'significant discrepancies' in revenue and PAT, then corrected via exchange letter. Signals internal controls weakness and audit quality gaps.

Earnings quality

High

Management claimed Q2 PAT margin 11.88% but delivered NPM 4.5% — a 7.4pp overstatement. Suggests either misstatement (claimed EBITDA as PAT) or unreconciled actuals. Investor reliance on management profit forecasts undermined.

Operational & execution

High

500+ dialysis machines in trial phase with Jan 27 launch target. Cancer screening, CAR-T, genomics products also pre-revenue. Revenue growth dependent on successful commercialization; execution and regulatory delays could derail targets.

Capital structure

Medium

Renewable energy demerger (LED/solar) targeted March 27 but gated on NCLT approval. If delayed, management's ability to fund CapEx for IVD/MedTech expansion may tighten. Demerger could reduce parent company's capital base.

Competitive & market

Medium

MedTech and IVD segments dominated by multinational players and large Indian companies (Apollo, Fortis, diagnostics labs). Lord's Mark's emerging brand and pre-launch products face execution and pricing pressure.

Management

Score 6/10. Clear on product specifics and technology differentiation (Renalyх, cancer screening). But evasive on stock price and constrained in detailed financial explanation. Reporting error erodes clarity on earnings accuracy. Early-stage company; limited track record. Dialysis machine orders (500+) and regulatory approvals on schedule. But significant reporting error signals execution lapses in financial controls.

What to watch next
  • 1 · Dec 2026 / Jan 2027

    Renalyх RXT 21 dialysis machine commercial launch and UK market entry

  • 2 · Jan 2027

    Sickle cell screening and breast cancer screening device launches

  • 3 · Feb–Mar 2027

    CAR-T clinical trials begin; Onco Diagnoscope trial outcomes expected

Delivered Q2 PAT fell 48% QoQ despite revenue growth, and management's claimed PAT margin (11.88%) vastly exceeds delivered NPM (4.5%), signaling either a misstatement or a data accuracy issue.

Informational and educational content only. Not investment advice.